Rational Design of Coagulation Factor VIIa Variants with Substantially Increased Intrinsic Activity

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2001 Nov 8

PMID 11698657

Citations 32

Authors

E Persson

M Kjalke

O H Olsen

Affiliations

Soon will be listed here.

Abstract

A trace amount of coagulation factor VII (FVII) circulates in the blood in the activated form, FVIIa (EC 3.4.21.21), formed by internal proteolysis. To avoid disseminated thrombus formation, FVIIa remains in a conformation with zymogen-like properties. Association with tissue factor (TF), locally exposed upon vascular injury, is necessary to render FVIIa biologically active and initiate blood clotting. We have designed potent mutants of FVIIa by replacing residues believed to function as determinants for the inherent zymogenicity. The TF-independent rate of factor X activation was dramatically improved, up to about 100-fold faster than that obtained with the wild-type enzyme and close to that of the FVIIa-soluble TF complex. The mutants appear to retain the substrate specificity of the parent enzyme and can be further stimulated by TF. Insights into the mechanism behind the increased activity of the mutants, presumably also pertinent to the TF-induced, allosteric stimulation of FVIIa activity, were obtained by studying their calcium dependence and the accessibility of the N terminus of the protease domain to chemical modification. The FVIIa analogues promise to offer a more efficacious treatment of bleeding episodes especially in hemophiliacs with inhibitory antibodies precluding conventional replacement therapy.

Citing Articles

Recombinant factor VIIa: new insights into the mechanism of action through product innovation.

Escobar M, Hoffman M, Castaman G, Hermans C, Mahlangu J, Oldenburg J Res Pract Thromb Haemost. 2025; 9(1):102670.

PMID: 39990097 PMC: 11847032. DOI: 10.1016/j.rpth.2024.102670.

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders.

Gandhi P, Zivkovic M, Ostergaard H, Bonde A, Elm T, Lovgreen M Nat Cardiovasc Res. 2024; 3(2):166-185.

PMID: 39196196 PMC: 11358003. DOI: 10.1038/s44161-023-00418-4.

The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity.

Jankowski W, Kidchob C, Bunce C, Cloake E, Resende R, Sauna Z Front Immunol. 2023; 14:1271120.

PMID: 37915568 PMC: 10616951. DOI: 10.3389/fimmu.2023.1271120.

Uncovering Membrane-Bound Models of Coagulation Factors by Combined Experimental and Computational Approaches.

Ohkubo Y, Madsen J Thromb Haemost. 2021; 121(9):1122-1137.

PMID: 34214998 PMC: 8432591. DOI: 10.1055/s-0040-1722187.

Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain.

Madsen J, Olsen O Biomolecules. 2021; 11(4).

PMID: 33917935 PMC: 8068379. DOI: 10.3390/biom11040549.

References

Petersen L, Persson E, Freskgard P . Thermal effects on an enzymatically latent conformation of coagulation factor VIIa. Eur J Biochem. 1999; 261(1):124-9. DOI: 10.1046/j.1432-1327.1999.00258.x. View

Petrovan R, Ruf W . Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem. 2000; 276(9):6616-20. DOI: 10.1074/jbc.M004726200. View

Dickinson C, Kelly C, Ruf W . Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci U S A. 1996; 93(25):14379-84. PMC: 26140. DOI: 10.1073/pnas.93.25.14379. View

Higashi S, Nishimura H, Aita K, Iwanaga S . Identification of regions of bovine factor VII essential for binding to tissue factor. J Biol Chem. 1994; 269(29):18891-8. View

Soejima K, Mizuguchi J, Yuguchi M, Nakagaki T, Higashi S, Iwanaga S . Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property. J Biol Chem. 2001; 276(20):17229-35. DOI: 10.1074/jbc.M009206200. View

Persson E, Nielsen L . Site-directed mutagenesis but not gamma-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor. FEBS Lett. 1996; 385(3):241-3. DOI: 10.1016/0014-5793(96)00400-0. View

Banner D, Darcy A, Chene C, Winkler F, Guha A, Konigsberg W . The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996; 380(6569):41-6. DOI: 10.1038/380041a0. View

Persson E . Influence of the gamma-carboxyglutamic acid-rich domain and hydrophobic stack of factor VIIa on tissue factor binding. Haemostasis. 1996; 26 Suppl 1:31-4. DOI: 10.1159/000217237. View

Freskgard P, Olsen O, Persson E . Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy. Protein Sci. 1996; 5(8):1531-40. PMC: 2143475. DOI: 10.1002/pro.5560050809. View

10.

Persson E, Nielsen L, Olsen O . Substitution of aspartic acid for methionine-306 in factor VIIa abolishes the allosteric linkage between the active site and the binding interface with tissue factor. Biochemistry. 2001; 40(11):3251-6. DOI: 10.1021/bi001612z. View

11.

Persson E, Olsen O, Ostergaard A, Nielsen L . Ca2+ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity. J Biol Chem. 1997; 272(32):19919-24. DOI: 10.1074/jbc.272.32.19919. View

12.

Dennis M, Eigenbrot C, Skelton N, Ultsch M, Santell L, Dwyer M . Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature. 2000; 404(6777):465-70. DOI: 10.1038/35006574. View

13.

PEDERSEN A, Nordfang O, Norris F, Wiberg F, Christensen P, Moeller K . Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem. 1990; 265(28):16786-93. View

14.

Sorensen B, Persson E, Freskgard P, Kjalke M, Ezban M, Williams T . Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem. 1997; 272(18):11863-8. DOI: 10.1074/jbc.272.18.11863. View

15.

Monroe D, Roberts H, Hoffman M . Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 1994; 88(2):364-71. DOI: 10.1111/j.1365-2141.1994.tb05032.x. View

16.

Kjalke M, Oliver J, Monroe D, Hoffman M, Ezban M, Hedner U . The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost. 1997; 78(4):1202-8. View

17.

Monroe D, Hoffman M, Oliver J, Roberts H . Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997; 99(3):542-7. DOI: 10.1046/j.1365-2141.1997.4463256.x. View

18.

Thim L, Bjoern S, Christensen M, Nicolaisen E, Lund-Hansen T, PEDERSEN A . Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry. 1988; 27(20):7785-93. DOI: 10.1021/bi00420a030. View

19.

Davie E, Fujikawa K, Kisiel W . The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991; 30(43):10363-70. DOI: 10.1021/bi00107a001. View

20.

LEONARD B, Clarke B, Sridhara S, Kelley R, Ofosu F, Blajchman M . Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII. J Biol Chem. 2000; 275(45):34894-900. DOI: 10.1074/jbc.M001166200. View